Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Oct 2025 Planned End Date changed from 19 Dec 2025 to 30 Jan 2026.
25 Aug 2025 According to a Merck and Co media release, the rationale and design of the Phase 2 study CADENCE trial will be featured, in an oral presentation at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 - September 1.
08 Aug 2025 Planned End Date changed from 12 Sep 2025 to 19 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com